[Effect of tactivin on cytotoxicity of blood lymphocytes in chronic myeloproliferative diseases].
The author studied natural cellular cytotoxicity (NCC) and antibody-dependent cytotoxicity (ADC) in lymphocytes from 31 patients with chronic myeloid leukemia (CML) and 37 patients with subleukemic myeloleukemia (SLM) in active clinical stage. The above parameters were found low in both diseases. Cytostatic therapy for CML did not affect NCC, but inhibited ADC. SLM treatment with myelobromol inhibited both cytotoxic responses. Combined therapy with adjuvant tactivin stimulated cytotoxic reactions activity. Tactivin positive effects persisted for two months.
Guseva
S A
SA
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D002908:Chronic Disease; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000494:pharmacology*; D013949:Thymus Extracts / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
Vliianie taktivina na tsitotoksichnost' limfotsitov krovi pri khronicheskikh mieloproliferativnykh zabolevaniiakh.